Optimization of pediatric rheumatology therapeutics

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 4, 2012, Pages 597-606

  Becker, M L ^a  

^a CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ACETYLSALICYLIC ACID; ADALIMUMAB; AZATHIOPRINE; BIOLOGICAL MARKER; CALCIUM BINDING PROTEIN; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOID RELATED PROTEIN 14; MYELOID RELATED PROTEIN 8; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; SALICYLIC ACID DERIVATIVE; TACROLIMUS; THIOPURINE METHYLTRANSFERASE; TOCILIZUMAB; TOLMENTIN SODIUM; UNCLASSIFIED DRUG;

ARTICLE; AUTOINFLAMMATORY DISEASE; BONE MARROW SUPPRESSION; DERMATOMYOSITIS; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LEUKOPENIA; LIVER FUNCTION TEST; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; RHEUMATIC DISEASE; RHEUMATIC FEVER; RHEUMATOID ARTHRITIS; SCLERODERMA; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS;

BIOLOGICAL MARKERS; HUMANS; PEDIATRICS; PHARMACOGENETICS; RHEUMATIC DISEASES;

EID: 84858794190     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.293     Document Type: Article

References (77)

1. Schaller, J.G. The history of pediatric rheumatology. Pediatr. Res. 58, 997-1007 (2005). (Pubitemid 41511078)
2. Diamantberger, M. Du rhumatisme noueux (polyarthrite deformante) chez les enfants. Lecrosnier et Babe. 1891, Paris.
3. Cornil, M. [Report on the pathology of chronic articular rheumatism]. Compterendu Med. Soc. Bio. Series (Paris) 4, 3-6 (1864).
4. Stone, E. An account of the success of the bark of the willow tree in the cure of the agues. Philos. Trans. R. Soc. Lond. 53, 195-200 (1763).
5. Schlesinger, B. The relationship of throat infection to acute rheumatism in childhood. Arch. Dis. Child. 5, 411-430 (1930).
6. Denny, F.W., Wannamaker, L.W., Brink, W.R., Rammelkamp, C.H. Jr & Custer, E.A. Prevention of rheumatic fever; treatment of the preceding streptococcic infection. J. Am. Med. Assoc. 143, 151-153 (1950).
7. Still, G.F. On a form of chronic joint disease in children. Med. Chir. Trans. 80, 47-60.9 (1897).
8. Short, C.L., Bauer, W., & Reynolds, W.E. Rheumatoid Arthritis: A Definition of the Disease and a Clinical Description Based on a Numerical Study of 293 Patients and Controls 480 (Harvard University Press, Cambridge, MA, 1957).
9. Levinson, J.E., Baum, J., Brewer, E. Jr, Fink, C., Hanson, V. & Schaller, J. Comparison of tolmetin sodium and aspirin in the treatment of juvenile rheumatoid arthritis. J. Pediatr. 91, 799-804 (1977). (Pubitemid 8207613)
10. Giannini, E.H. & Brewer, E.J. Jr. Standard methodology for Segment I, II, and III Pediatric Rheumatology Collaborative Study Group studies. II. Analysis and presentation of data. J. Rheumatol. 9, 114-122 (1982). (Pubitemid 12091049)
11. Brewer, E.J. Jr & Giannini, E.H. Standard methodology for Segment I, II, and III Pediatric Rheumatology Collaborative Study Group studies. I. Design. J. Rheumatol. 9, 109-113 (1982). (Pubitemid 12091048)
12. Giannini, E.H. et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N. Engl. J. Med. 326, 1043-1049 (1992).
13. Beukelman, T. et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. (Hoboken). 63, 465-482 (2011).
14. Wilson, J.T. An update on the therapeutic orphan. Pediatrics 104, 585-590 (1999). (Pubitemid 29426624)
15. Guiducci, C. et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 465, 937-941 (2010).
16. Kearns, G.L. Beyond biomarkers: an opportunity to address the 'pharmacodynamic gap' in pediatric drug development. Biomark. Med. 4, 783-786 (2010).
17. Savage, W.J. & Everett, A.D. Biomarkers in pediatrics: children as biomarker orphans. Proteomics. Clin. Appl. 4, 915-921 (2010).
18. Petty, R.E. et al.; International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 31, 390-392 (2004). (Pubitemid 38160763)
19. Beresford, M.W. Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy. Paediatr. Drugs 13, 161-173 (2011).
20. Wallace, C.A., Ruperto, N. & Giannini, E.; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J. Rheumatol. 31, 2290-2294 (2004). (Pubitemid 39453253)
21. Wallace, C.A., Huang, B., Bandeira, M., Ravelli, A. & Giannini, E.H. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum. 52, 3554-3562 (2005). (Pubitemid 41612224)
22. Ruperto, N. et al.; Pediatric Rheumatology International Trials Organization. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 50, 2191-2201 (2004). (Pubitemid 38924397)
23. Cronstein, B.N., Naime, D. & Ostad, E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J. Clin. Invest. 92, 2675-2682 (1993). (Pubitemid 24006532)
24. Allegra, C.J., Chabner, B.A., Drake, J.C., Lutz, R., Rodbard, D. & Jolivet, J. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J. Biol. Chem. 260, 9720-9726 (1985). (Pubitemid 15013030)
25. Chabner, B.A. et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J. Clin. Invest. 76, 907-912 (1985).
26. Schrøder, H. & Fogh, K. Methotrexate and its polyglutamate derivatives in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukemia. Cancer Chemother. Pharmacol. 21, 145-149 (1988). (Pubitemid 18087030)
27. Wallace, C.A., Bleyer, W.A., Sherry, D.D., Salmonson, K.L. & Wedgwood, R.J. Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum. 32, 677-681 (1989). (Pubitemid 19179246)
28. Ravelli, A. et al. Plasma levels after oral methotrexate in children with juvenile rheumatoid arthritis. J. Rheumatol. 20, 1573-1577 (1993). (Pubitemid 24027335)
29. Dervieux, T. et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 50, 2766-2774 (2004). (Pubitemid 39209513)
30. Becker, M.L. et al. Analysis of intracellular methotrexate polyglutamates in patients with juvenile idiopathic arthritis: effect of route of administration on variability in intracellular methotrexate polyglutamate concentrations. Arthritis Rheum. 62, 1803-1812 (2010).
31. van Haandel, L., Becker, M.L., Leeder, J.S., Williams, T.D. & Stobaugh, J.F. A novel high-performance liquid chromatography/mass spectrometry method for improved selective and sensitive measurement of methotrexate polyglutamation status in human red blood cells. Rapid Commun. Mass Spectrom. 23, 3693-3702 (2009).
32. Becker, M.L. et al. The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response. Arthritis Rheum. 63, 276-285 (2011).
33. Wallace, C.A., Sherry, D.D., Mellins, E.D. & Aiken, R.P. Predicting remission in juvenile rheumatoid arthritis with methotrexate treatment. J. Rheumatol. 20, 118-122 (1993). (Pubitemid 23049194)
34. Foell, D., Frosch, M., Schulze zur Wiesch, A., Vogl, T., Sorg, C. & Roth, J. Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop? Ann. Rheum. Dis. 63, 206-208 (2004). (Pubitemid 38122142)
35. Foell, D. et al.; Paediatric Rheumatology International Trials Organization (PRINTO). Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 303, 1266-1273 (2010).
36. Vogl, T. et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat. Med. 13, 1042-1049 (2007). (Pubitemid 47517513)
37. Frosch, M. et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 43, 628-637 (2000). (Pubitemid 30394955)
38. Schulze zur Wiesch, A., Foell, D., Frosch, M., Vogl, T., Sorg, C. & Roth, J. Myeloid related proteins MRP8/MRP14 may predict disease flares in juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 22, 368-373 (2004). (Pubitemid 38585243)
39. Giannini, E.H., Ruperto, N., Ravelli, A., Lovell, D.J., Felson, D.T. & Martini, A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 40, 1202-1209 (1997). (Pubitemid 27430130)
40. Consolaro, A. et al.; Paediatric Rheumatology International Trials Organisation. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 61, 658-666 (2009).
41. Magni-Manzoni, S. et al. Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. Arthritis Rheum. 59, 1120-1127 (2008).
42. Brunner, H.I., Lovell, D.J., Finck, B.K. & Giannini, E.H. Preliminary definition of disease flare in juvenile rheumatoid arthritis. J. Rheumatol. 29, 1058-1064 (2002). (Pubitemid 34493514)
43. Nistala, K. et al. Clinical assessment and core outcome variables are poor predictors of hip arthritis diagnosed by MRI in juvenile idiopathic arthritis. Rheumatology (Oxford). 46, 699-702 (2007). (Pubitemid 46523320)
44. Malattia, C. et al. Dynamic contrast-enhanced magnetic resonance imaging in the assessment of disease activity in patients with juvenile idiopathic arthritis. Rheumatology (Oxford). 49, 178-185 (2010).
45. Shanmugavel, C. et al. Role of power Doppler sonography in evaluation of therapeutic response of the knee in juvenile rheumatoid arthritis. Rheumatol. Int. 28, 573-578 (2008).
46. Becker, M.L. & Leeder, J.S. Identifying genomic and developmental causes of adverse drug reactions in children. Pharmacogenomics 11, 1591-1602 (2010).
47. Cassidy, P. & Petty, R.E. eds. Textbook of Pediatric Rheumatology 5th edn. (Saunders, Philadelphia, PA, 2205).
48. MAIBACH, H.I. & EPSTEIN, W.L. Immunologic responses of healthy volunteers receiving azathioprine (IMURAN). Int. Arch. Allergy Appl. Immunol. 27, 102-109 (1965).
49. Stolk, J.N. et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum. 41, 1858-1866 (1998). (Pubitemid 28465541)
50. Lennard, L., Van Loon, J.A. & Weinshilboum, R.M. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin. Pharmacol. Ther. 46, 149-154 (1989). (Pubitemid 19219950)
51. Relling, M.V. et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl. Cancer Inst. 91, 2001-2008 (1999).
52. Ganiere-Monteil, C. et al. Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age. Eur. J. Clin. Pharmacol. 60, 89-96 (2004). (Pubitemid 38626437)
53. Park-Hah, J.O., Klemetsdal, B., Lysaa, R., Choi, K.H. & Aarbakke, J. Thiopurine methyltransferase activity in a Korean population sample of children. Clin. Pharmacol. Ther. 60, 68-74 (1996). (Pubitemid 26279223)
54. Stocco, G. et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin. Pharmacol. Ther. 85, 164-172 (2009).
55. Roblin, X., Oussalah, A., Chevaux, J.B., Sparrow, M. & Peyrin-Biroulet, L. Use of thiopurine testing in the management of inflammatory bowel diseases in clinical practice: A worldwide survey of experts. Inflamm. Bowel Dis. 17, 2480-2487 (2011).
56. Sherwin, C.M., Fukuda, T., Brunner, H.I., Goebel, J. & Vinks, A.A. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin. Pharmacokinet. 50, 1-24 (2011).
57. Barraclough, K.A., Lee, K.J. & Staatz, C.E. Pharmacogenetic influences on mycophenolate therapy. Pharmacogenomics 11, 369-390 (2010).
58. Baldelli, S. et al. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics 8, 1127-1141 (2007). (Pubitemid 47578222)
59. Lévesque, E. et al. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin. Pharmacol. Ther. 81, 392-400 (2007). (Pubitemid 46364482)
60. van Gelder, T. et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 86, 1043-1051 (2008).
61. Gaston, R.S. et al. Fixed-or controlled-dose mycophenolate mofetil with standard-or reduced-dose calcineurin inhibitors: the Opticept trial. Am. J. Transplant. 9, 1607-1619 (2009).
62. Zhao, W. et al. Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients. J. Clin. Pharmacol. 50, 1280-1291 (2010).
63. Sagcal-Gironella, A.C. et al. Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. Semin. Arthritis Rheum. 40, 307-313 (2011).
64. Strassburg, C.P. et al. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 50, 259-265 (2002). (Pubitemid 34087942)
65. Allegaert, K., Vanhaesebrouck, S., Verbesselt, R. & van den Anker, J.N. In vivo glucuronidation activity of drugs in neonates: extensive interindividual variability despite their young age. Ther. Drug Monit. 31, 411-415 (2009).
66. Zhao, W., Fakhoury, M. & Jacqz-Aigrain, E. Developmental pharmacogenetics of immunosuppressants in pediatric organ transplantation. Ther. Drug Monit. 32, 688-699 (2010).
67. Filler, G., Foster, J., Berard, R., Mai, I. & Lepage, N. Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. Transplant. Proc. 36, 1327-1331 (2004). (Pubitemid 38902969)
68. Scott, D.L. & Kingsley, G.H. Tumor necrosis factor inhibitors for rheumatoid arthritis. N. Engl. J. Med. 355, 704-712 (2006).
69. Maini, R.N. et al. Therapeutic efficacy of multiple intravenous infusions of antitumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41, 1552-1563 (1998). (Pubitemid 28459913)
70. Wolbink, G.J. et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 54, 711-715 (2006).
71. Ruperto, N. et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann. Rheum. Dis. 69, 718-722 (2010).
72. Baert, F. et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348, 601-608 (2003). (Pubitemid 36204954)
73. Bartelds, G.M. et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann. Rheum. Dis. 66, 921-926 (2007). (Pubitemid 46999794)
74. van der Laken, C.J. et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann. Rheum. Dis. 66, 253-256 (2007). (Pubitemid 46226064)
75. Ruperto, N. Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1b antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study. Pediatric Rheumatology 9 (suppl. 1), O21 (2011).
76. Becker, M.L. et al. Analysis of intracellular methotrexate polyglutamates in juvenile idiopathic arthritis: Effect of route of administration upon intracellular methotrexate polyglutamate variability Arthritis Rheum. 62, 1803-1812 (2010).
77. Bartelds, G.M. et al. Clinical response to adalimumab: relationship to antiadalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 66, 921-926 (2007). (Pubitemid 46999794)